Research programme: T lymphocyte immunotherapies - Juno Therapeutics

Drug Profile

Research programme: T lymphocyte immunotherapies - Juno Therapeutics

Alternative Names: CAR T cell products - Juno Therapeutics; CARTs - Juno Therapeutics; Chimeric antigen receptor T lymphocytes - Juno Therapeutics; High-affinity TCR T cells; TCR T cell products - Juno Therapeutics

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juno Therapeutics; Peter MacCallum Cancer Centre
  • Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics; Memorial Sloan-Kettering Cancer Center; Seattle Childrens Research Institute
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
  • 16 Nov 2016 Juno Therapeutics plans a phase I trial for Solid tumours in Australia (ACTRN12616001580460)
  • 11 Apr 2016 T lymphocyte immunotherapies licensed to Celgene worldwide except North America and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top